New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
08:05 EDTJAZZJazz Pharmaceuticals agrees to acquire rights to defibrotide in Americas
Jazz Pharmaceuticals announced that the company has signed a definitive agreement with Sigma-Tau Pharmaceuticals under which a subsidiary of Jazz Pharmaceuticals will acquire from Sigma-Tau rights to defibrotide in the United States and all other countries in the Americas. Sigma-Tau holds rights to market defibrotide in the Americas under an agreement with Gentium S.p.A., which was acquired by Jazz earlier this year. As part of the agreement, Sigma-Tau would receive an upfront payment of $75M upon closing of the transaction. Sigma-Tau would be eligible to receive milestone payments of $25M upon the acceptance for filing by the FDA of the first NDA for defibrotide for VOD and up to an additional $150M based on the timing of potential FDA approval of defibrotide for VOD. Jazz expects to fund the transaction with cash on hand and that the transaction will close during the third quarter of 2014, subject to customary closing conditions, including expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
News For JAZZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
09:24 EDTJAZZJefferies sees Pharma M&A continuing, lists 22 possible targets
Jefferies analyst David Steinberg believes the M&A wave in the Pharmaceuticals space that began in 2005 can continue as the key drivers remain largely intact. In a note titled "Who is Next? The Feeding Frenzy in Specialty Pharmaceuticals," Steinberg sees deals continuing amid cheap debt, the push for lower corporate taxes and investors rewarding many acquirers for their transactions. He points out there are now around 100 publicly traded Specialty Pharmaceutical companies following the recent life sciences IPO boom. Potential takeover targets, according to Steinberg, include Valeant (VRX), Shire (SHPG), Perrigo (PRGO), Zoetis (ZTS), Mallinckrodt (MNK), Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), Pacira (PCRX), Indivior, Insys Therapeutics (INSY), The Medicines Co. (MDCO), Depomed (DEPO), Spectrum (SPPI), KYTHERA (KYTH), Revance (RVNC), XenoPort (XNPT), Mylan (MYL), Akorn (AKRX), Impax (IPXL), Amphastar Pharmaceuticals (AMPH), Anacor (ANAC) and BioDelivery Sciences (BDSI).
May 27, 2015
18:18 EDTJAZZRosewind acquires ProstaScint assets from Jazz Pharmaceuticals
In a regulatory filing earlier, Ampio Pharmaceuticals (AMPE) reported that on May 20, Rosewind, an approximately 81.5%-owned subsidiary of Ampio, entered into and closed on an asset purchase agreement with Jazz Pharmaceuticals (JAZZ). Pursuant to the agreement, Rosewind purchased assets related to ProstaScint, or capromab pendetide, including certain intellectual property and contracts, and the product approvals, inventory and work in progress, and assumed certain of Jazz's liabilities, including those related to product approvals and the sale and marketing of ProstaScint. Rosewind paid $1M at closing for the ProstaScint assets. Rosewind has also agreed to pay an additional $500,000 within five days after transfer for the ProstaScint-related product inventory, and $226,523 payable on September 30, which represents a portion of certain United States Food and Drug Administration fees. Rosewind also will pay 8% on net sales made after October 31, 2017, payable up to a maximum aggregate payment of $2.5M. The agreement also provides that for a period of one year, Jazz agrees to not directly or indirectly, through any of its agents or affiliates, compete against ProstaScint, or acquire a company or business in which more than 15% of such acquired business’ total revenue is generated by products that compete with ProstaScint.
May 20, 2015
08:12 EDTJAZZJazz Pharmaceuticals management to meet with Leerink
Subscribe for More Information
07:21 EDTJAZZUBS to hold a conference
Subscribe for More Information
May 18, 2015
12:24 EDTJAZZJazz Pharmaceuticals management to meet with Guggenheim
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use